Search Clinical Trials in the European Union

>2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
861-880 of 1,743 trials

Brain Radionecrosis: Bevacizumab vs. Placebo

We are studying whether adding bevacizumab to standard corticosteroid therapy helps improve symptoms and reduce steroid use in patients with brain radionecrosis after radiotherapy. This trial also looks at safety and quality of life.

Brain Metastases and Radionecrosis>2 yearsConfirmation phase (III)≤5 visitsInvestigational MedicinesNeurologyOncology

Neuroendocrine Neoplasms: Metronomic Temozolomide Study

We are investigating the effects of low-dose Temozolomide in patients with advanced neuroendocrine neoplasms who are not fit for traditional treatments. The goal is to see if this approach can improve survival and quality of life.

Neuroendocrine Carcinoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesInternal MedicineOncology

Advanced Solid Tumors: PAS-004 Treatment Study

We are testing a new drug for patients with advanced solid tumors that have specific genetic mutations. The study aims to assess the safety and how the body handles this treatment in those who have not responded to other therapies.

Malignant Mast Cell Tumors>2 yearsSafety phase (I)Oncology

Pain Relief After Esophageal Procedure: Levobupivacaine Study

We are testing a local anesthetic to see if it helps reduce pain after endoscopic submucosal dissection for esophageal lesions. The study will also look at its safety and impact on recovery time.

Visible Esophageal Lesions (Pre-cancerous)>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesGastroenterologyInternal MedicineOtolaryngology

Hip Replacement: Antibiotic Impregnated Bone Graft Study

We are investigating whether a new antibiotic-infused bone graft can reduce the risk of infection after hip replacement surgery. This study compares it to a standard graft to see which is more effective and safe.

Prosthetic Joint Infection>2 yearsEfficacy phase (II)≤5 visitsStandard MedicinesInfectious DiseasesOrthopedics and Traumatology

Acute Graft Versus Host Disease: Siltuximab Treatment

We are studying the effects of siltuximab combined with corticosteroids for patients with severe acute graft versus host disease affecting the liver and gut. The goal is to see if this treatment is effective and safe for first-line therapy.

Acute Graft Versus Host Disease (GVHD)>2 yearsEfficacy phase (II)HematologyInternal Medicine

Cytoreductive Surgery: Albumin and Ringer Lactate Study

We are testing whether a combination of 20% albumin and Ringer Lactate improves recovery after surgery for patients with peritoneal carcinosis. This study compares it to Ringer Lactate alone to see which is more effective.

Peritoneal Carcinomatosis>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesPartially RemoteGastroenterologyGynecology and ObstetricsInternal MedicineOncology

Regorafenib for Recurrent Grade 2 and 3 Meningioma

We are studying whether Regorafenib can help patients with recurrent grade 2 and 3 meningiomas live longer without disease progression after surgery and radiotherapy. The trial also looks at overall survival, quality of life, and potential side effects.

Malignant Meningioma>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesNeurologyOncology

Lymphoma Treatment: MK-3475A Study

We are testing a new formulation of pembrolizumab for patients with relapsed or refractory classical Hodgkin lymphoma or primary mediastinal large B-cell lymphoma. The study aims to evaluate its effectiveness and safety compared to existing treatments.

Relapsed or Refractory Classical Hodgkin LymphomaRelapsed or Refractory Primary Mediastinal Large B-cell Lymphoma>2 yearsEfficacy phase (II)16-20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Dexamethasone for Advanced Multiple Myeloma

We are studying a free treatment regimen of Dexamethasone for patients with advanced relapsed or refractory multiple myeloma. The goal is to see how well it works in improving response rates and quality of life.

Multiple Myeloma>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesHematologyOncology

Mucopolysaccharidosis Type II: DNL310 vs Idursulfase

We are studying a new treatment, DNL310, for children and young adults with Mucopolysaccharidosis Type II to see if it works better than the current treatment, Idursulfase, in improving brain and physical health.

Hunter's Syndrome>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementHematologyNeurology

Advanced Solid Tumors: IDE397 Treatment Study

We are evaluating a new drug, IDE397, for adults with advanced solid tumors to see how safe it is and how the body responds to it. This study aims to gather important information about its effects on cancer.

Advanced Solid Tumors>2 yearsSafety phase (I)Oncology

Neuroendocrine Tumors: Lutathera® Treatment Study

We are studying whether additional cycles of Lutathera® can help patients with new progression of intestinal well-differentiated neuroendocrine tumors. This trial compares the treatment to active monitoring to see which approach is more effective.

Neuroendocrine Tumor>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Systemic Sclerosis Prevention: Clopidogrel Study

We are investigating if Clopidogrel can reduce the risk of developing systemic sclerosis in patients with specific immune conditions and Raynaud phenomenon. The study compares its effects to a placebo over several years.

Raynaud Phenomenon>2 yearsEfficacy phase (II)Confirmation phase (III)Investigational MedicinesInternal MedicineRheumatology

Chronic Kidney Disease: BI 690517 with Empagliflozin

We are studying whether a new daily pill can help prevent worsening kidney disease and heart problems in people with chronic kidney disease. Participants will compare this treatment to a placebo to see its effects.

Chronic Kidney Disease>2 yearsConfirmation phase (III)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyNephrology

Takotsubo Syndrome: Cyclosporine A Treatment Study

We are investigating whether cyclosporine A can help reduce heart damage in patients with Takotsubo syndrome compared to a placebo. This study aims to improve treatment options for this heart condition.

Healthy Participants>2 yearsEfficacy phase (II)6-10 visitsStandard MedicinesCardiologyInternal Medicine

Simvastatin for Primary Sclerosing Cholangitis (PSC)

We are studying whether simvastatin can help people with PSC live longer without serious complications like bile duct cancer or the need for a transplant. We will also examine its effects on disease markers and symptoms.

Primary Sclerosing Cholangitis>2 yearsEfficacy phase (II)Standard MedicinesHepatologyOncology

B-Cell Blood Cancers: AZD5492 Treatment Study

We are investigating whether AZD5492 is safe and effective for adults with relapsed or refractory B-cell malignancies, both on its own and with other cancer treatments.

B-Cell Malignancies>2 yearsSafety phase (I)No PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Non-Small Cell Lung Cancer: Immunotherapy and Chemotherapy Study

We are studying a treatment combining immunotherapy, chemotherapy, and radiotherapy for patients with newly diagnosed non-small cell lung cancer that has spread to a few other areas. The aim is to see if this approach helps patients live longer without their cancer worsening.

Non-small Cell Lung Cancer>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncologyPulmonology

CD30-Positive Lymphoma: Brentuximab Imaging Study

We are investigating how a drug called Brentuximab distributes in the body of patients with CD30-positive lymphoma. This study may help improve future treatments for this type of cancer.

High-Risk Diffuse Large B-Cell LymphomaLymphoma>2 yearsSafety phase (I)HematologyOncology